share_log

Ginkgo Bioworks | 4: Statement of changes in beneficial ownership of securities-Director DEKKERS MARIJN E

SEC announcement ·  Jun 15 04:27
Summary by Futu AI
On June 12, 2024, Marijn E. Dekkers, associated with Ginkgo Bioworks Holdings, Inc. [DNA], executed a transaction involving the acquisition of 105,263 shares of Class A Common Stock. This transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Dekkers directly holds a total of 386,480 shares. Additionally, Dekkers has an indirect beneficial ownership of 5,515,364 shares through Novalis LifeSciences Investments I, L.P. The transaction reflects a significant increase in Dekkers' direct stake in the company, while maintaining a substantial indirect position.
On June 12, 2024, Marijn E. Dekkers, associated with Ginkgo Bioworks Holdings, Inc. [DNA], executed a transaction involving the acquisition of 105,263 shares of Class A Common Stock. This transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Dekkers directly holds a total of 386,480 shares. Additionally, Dekkers has an indirect beneficial ownership of 5,515,364 shares through Novalis LifeSciences Investments I, L.P. The transaction reflects a significant increase in Dekkers' direct stake in the company, while maintaining a substantial indirect position.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.